Company Overview
Snapshot
Founded in June 2015 by Roi Paul Nathan and Ilana Nathan, Ela Pharma operates with 1–10 employees. The company has raised $77K across two funding rounds. In December 2020, Ela Pharma secured equity crowdfunding from Smart Funding.
Business overview
Ela Pharma is a biotechnology company focused on developing innovative drugs to address clinical conditions caused by necrosis. The company's drug-development process is built upon a novel anti-necrosis technology platform. Its core technology involves directly inhibiting an intracellular proteolytic enzyme critical to regulating necrosis pathways. Ela Pharma's initial anti-necrosis agents are small molecules designed to inhibit a specific cellular target, demonstrating significant efficacy at low concentrations. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development markets.
Log in to access full profile ›Company Intelligence Q&A
- When was Ela Pharma founded and by whom?
- Ela Pharma was founded in June 2015 by Roi Paul Nathan and Ilana Nathan.
- What is Ela Pharma's primary focus in drug development?
- Ela Pharma is focused on developing innovative drugs to address clinical conditions caused by necrosis, utilizing a new platform for anti-necrosis technology.
- What is the core mechanism of Ela Pharma's anti-necrosis technology?
- Ela Pharma's technology is based on directly inhibiting an intracellular proteolytic enzyme that plays a critical role in the regulation of necrosis pathways.